Optic Neuropathy Management Global Market Report 2025

The optic neuropathy management market size has grown strongly in recent years. It will grow from $3.62 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to the rising prevalence of optic neuropathy, an increasing number of eye injuries, greater investment in eye care services, growing demand for specialized eye care, and the rising incidence of diabetes and other chronic diseases.

The optic neuropathy management market size is expected to see strong growth in the next few years. It will grow to $4.85 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to the increasing number of individuals affected by amebic infections, a growing geriatric population, a rising prevalence of optic neuritis, a higher incidence of glaucoma, and an overall increase in optic neuritis cases. Key trends include advancements in medical technology, the rise of personalized medicine and telemedicine, technological improvements in diagnostic techniques, the expansion of healthcare infrastructure in emerging markets, and a growing focus on neuroprotective therapies.

The increasing prevalence of eye diseases is expected to drive the growth of the optic neuropathy management market in the coming years. Eye disease encompasses any condition that affects the structure or function of the eyes, leading to vision impairment or related symptoms. The rising occurrence of these conditions is influenced by factors such as aging populations, prolonged screen exposure, unhealthy lifestyle choices, and underlying health issues such as diabetes. Optic neuropathy management plays a crucial role in reducing the impact of eye diseases by preventing further optic nerve damage and preserving vision. For instance, in February 2025, the Department of Health and Social Care, a UK-based government department, reported that approximately 2 million people in the UK were living with some degree of sight loss, with projections indicating an increase to 2.7 million by 2030. As a result, the growing prevalence of eye disease is fueling the expansion of the optic neuropathy management market.

Leading companies in the optic neuropathy management market are focusing on innovative therapies, such as monoclonal antibody treatments, to gain a competitive edge. Monoclonal antibodies are lab-engineered proteins designed to mimic the immune system’s ability to fight harmful pathogens such as viruses and bacteria. For example, in March 2023, Horizon Therapeutics, an Ireland-based company, presented a new analysis of MRI findings for its drug, UPLIZNA (inebilizumab). The study revealed that UPLIZNA reduces the formation of asymptomatic optic nerve lesions in patients with neuromyelitis optica spectrum disorder (NMOSD). This underscores Horizon’s dedication to developing advanced treatments for rare conditions such as NMOSD, gout, and thyroid eye disease. UPLIZNA is a monoclonal antibody designed to target and eliminate harmful B cells, reducing inflammation and preventing further damage to the central nervous system and optic nerves, ultimately helping to prevent relapses and preserve vision.

In January 2024, Naya Biosciences, a US-based life sciences company, acquired Florida Biotechnologies for $20 million. This acquisition includes a gene therapy program aimed at treating Leber’s hereditary optic neuropathy (LHON), a rare genetic disorder that leads to vision loss. Florida Biotechnologies is a US-based gene therapy company specializing in treatments for mitochondrial diseases, including LHON.

Major players in the optic neuropathy management market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Aerie Pharmaceuticals, Neurophth Therapeutics, and AdvaCare.

North America was the largest region in the optic neuropathy management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in optic neuropathy management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the optic neuropathy management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Optic neuropathy management involves the diagnosis, treatment, and monitoring of optic nerve damage through medications, lifestyle modifications, surgical interventions, and vision rehabilitation to prevent further deterioration and improve visual function.

The primary treatment types for optic neuropathy management include medications, surgery, and other therapeutic approaches. Medications are used to treat, manage, or prevent diseases by altering bodily functions, such as reducing inflammation or protecting nerve function. Diagnosis typically involves imaging tests, blood tests, and other diagnostic procedures. Treatment is provided across various healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.

The optic neuropathy management market research report is one of a series of new reports that provides optic neuropathy management market statistics, including the optic neuropathy management industry global market size, regional shares, competitors with the optic neuropathy management market share, detailed optic neuropathy management market segments, market trends, and opportunities, and any further data you may need to thrive in the optic neuropathy management industry. This optic neuropathy management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The optic neuropathy management market consists of revenues earned by entities by providing services such as anti-inflammatory treatments, metabolic and nutritional support, and gene and stem cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The optic neuropathy management market includes sales of neuroprotective therapies, advanced imaging solutions, and AI-driven diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.